News & Updates

Jaktinib, a novel JAK and AVCR1 inhibitor, is more effective than hydroxyurea in patients with myelofibrosis, resulting in better spleen response with improved symptom response and less cytopenias, according to the results of a phase III study presented at EHA 2023.

Outcomes are significantly worse in patients diagnosed with type 2 myocardial infarction (MI) with objective evidence of myocardial ischaemia compared with those with myocardial injury and subjective type 2 MI, reports a study.

A technology-enabled virtual ward may be a feasible alternative to hospitalization for high-risk COVID-19 patients such as the elderly and the immunocompromised, a retrospective cohort study from Singapore suggests.

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

Use of renin-angiotensin system (RAS) inhibitors results in improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and advanced kidney disease, a study has shown.

A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.